By Liz Hoffmann - July 16, 2012 | Tickers: CVS, ESRX, WAG | 0 Comments Liz is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. What do sex, drugs, and paper towels have in common? They all have devotees who shop at CVS Caremark (NYSE: CVS). Whether it's young men and women for birth control, the sick and elderly for prescription drugs, or growing families for baby supplies and paper towels, you'll find them all at a CVS. And that's just the tip of the iceberg when it comes to the number of products distributed and demographic groups served. Now for some specifics: CVS has been on a respectable growth trajectory for the past 5 years, with revenues for that period increasing 19.57% and EPS growing at 10.11%. Dividends are paid quarterly and in 2012 have increased 30% versus the year ago perioddriving a 1.35% annualized dividend yield. And for the past 52 weeks, the stock has performed admirably logging a robust 27.44% increase in price. On Thursday, July 5th CVS reached its all-time high of $48.32 per share. It should be no surprise then that … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/pd8hns/medicinal_chemistr) has announced the addition of Elsevier Science and Technology's new report "Medicinal Chemistry of Anticancer Drugs" to their offering. Antitumour chemotherapy is nowadays a very active field of research, and a huge amount of information on the topic is generated every year. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book addresses the need for an updated treatment from the point of view of medicinal chemistry and drug design. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells. These therapies are in their infancy, but they hold promise of more effective therapies with fewer side effects. Resistance to antitumour drugs is another important but normally neglected field. The focus of Medicinal Chemistry of Anticancer Drugs is on the mechanism of action of antitumour drugs from the molecular point of view and on the relationship between chemical structure and chemical and biochemical reactivity of antitumour agents, aiming at the rationalization of the action of this type of drugs, which would allow the design of new active structures. - Presents information in a clear and concise … Continue reading →

16 July 2012 Last updated at 09:36 ET Keith Allen has defended a forthcoming Channel 4 series in which he is filmed taking drugs. The musician and actor took MDMA, the pure form of ecstasy, for the upcoming documentary to examine its effects. Health campaigners said the show ran the risk of being "voyeuristic" and "unrepresentative". But the 59-year-old actor and musician said the documentary was designed as a "forensic analysis" into the physical and psychological effects of drugs. Called Drugs Live, the "radical" four-part series aims to examine the claims and counterclaims made about recreational drugs by testing them in a monitored environment. TV bosses at Channel 4 said the series, to be broadcast in the autumn, would "provide viewers with unmediated access to a live drug trial". Speaking on ITV 1's This Morning, Allen said it was "insane" to suggest the show glamorised drug use. "If you think that I'm glamorising the taking of drugs by spending an hour and 20 minutes for two consecutive Mondays in an MRI scanning machine, then you're insane. We wouldn't want anyone to come away from the programme thinking that MDMA is benign. Read more here: Allen defends C4 Drugs Live show … Continue reading →